C Diff Treatment

There have been only 12 unique studies evaluating this treatment for the primary and secondary prevention of CDI, with only 1 conducted prospectively.

Clostridium difficile @CritCultivation #BJHM #MedEd #Medtwitter #Cdiff #GItwitter #IDtwitter #FOAMed #familymedicine #medstudenttwitter pic.twitter.com/459Bdz8xfl— Brown Hospital Medicine (@BrownJHM) August 26, 2022

The therapies for Clostridioides difficile infection (CDI) saw many developments in recent months and there are more exciting things to come.

Fecal microbiota transplant (FMT) is a promising option for patients struggling with CDI recurrences. But how can we ensure the treatment is successful?

Recurrent #CDI episodes can occur in 25% or more of patients, with a cycle of multiple recurrences in a single patient contributing to the complexity of care. #guthealth #GITwitter #cdiff pic.twitter.com/X2S11F8qow— Microbiome Science (@MbiomeScience) February 5, 2023

Intravenous metronidazole for fulminant Clostridioides difficile infection

Recognising when you reach obstacles. Pharmacist involvement in #CDiff management. Strength of having #MDT involvement in any #PatientSafety #SocialScience aspects of #SurgicalAntimicrobialProphylaxis #SAP #AMS #AMR Need to consider sociocultural identities in relation to #IPC 🙌🏼 https://t.co/h8JpWZnFYV— Lilian Chiwera (@lilian_chiwera) February 4, 2023

Patients with cystic fibrosis are typically administered antibiotics throughout their lives, which can increase the risk for C difficile infections.

Though the drug is initially more expensive, treating C diff infection with fidaxomicin reduced costs overall by reducing CDI recurrences.

24) The answer is D. #Loperamide is an adjunctive for use after confirmation of negative #Cdiff and management of underlying immune colitis with #prednisone. For steroid-refractory cases, or for patients in extremis, infliximab and vedolizumab are reasonable options— pulmmed_ce (@Pulmmed_CE) February 1, 2023

The Centers for Disease Control and Prevention identifies Clostridioides difficile infection (CDI) as an urgent threat to people and...

We examine the patient pathway and variations in clinical practice and identify, synthesize insights on and discuss associated challenges. Examples of key challenges include the need to conduct multiple tests for a conclusive diagnosis, treatment side-effects, the cost of some antibiotics and barrie …

We examine the patient pathway and variations in clinical practice and identify, synthesize insights on and discuss associated challenges. Examples of key challenges include the need to conduct multiple tests for a conclusive diagnosis, treatment side-effects, the cost of some antibiotics and barrie …

MDR colonization was associated with MDR infection and colonization and infection was linked to higher numbers and duration of antibiotic use.

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin.

Sky-high costs with little wiggle room to negotiate mean fidaxomicin remains underprescribed for recurrent C diff, despite favorable outcomes.

Clostridioides difficile infection poses significant clinical challenges due to its recurrent nature. Current antibiotic management does not address the underlying issue, that of a disturbed gastrointestinal microbiome, called dysbiosis. This provides a supportive environment for the germinat …

“#FreeWebinar: Feb. 7, 12p ET Register at https://t.co/Up6AGfH2hR 1 Hr CE: RN, CCM, SW, CME, ACPE The CDC identifies #Cdiff as an urgent threat to healthcare systems. Learn strategies to reduce recurrence, hospital admissions, & poor quality of life. #CMSA #CaseManagement”

The number of 30-day hospital readmissions because of CDI increased between 2010-2017.

Of 2650 patients, 86 were diagnosed with CDI during 90,833 hospital-days (0.95/1000 hospital-days); CDI prevalence was 3.2%. CDI incidence varied in timing; 0.3% patients had CDI pre-ICU, 2.2% in the ICU; an 0.8% developed CDI post-ICU. Relapse or recurrence of CDI was documented in 9.3% patients. I …

RBX2660 is efficacious and safe in older adults with recurrent CDI and underlying comorbidities.

Fidaxomicin, a macrocyclic antibiotic, selectively kills Clostridioides difficile and reduces C. difficile infection (CDI) recurrence compared with vancomycin, but some studies and guidelines report fidaxomicin as being less cost-effective. The aim of this study was to compare the cost …

Exciting day 2 at #GCCAMR23 for us! Our senior fellow (T32) @TarynEubank presented her work on vancomycin non-susceptibility #cdiff #AMR pic.twitter.com/R3VlZz9N7F— The Garey Lab (@TheGareyLab) January 19, 2023

Excellent talk by @DrJessicaA on #CDiff at @CedarsSinai IM grand rounds. @AmCollegeGastro guidelines recommend AGAINST probiotics after treating for C. Diff--can actually delay reconstitution of the #microbiome! @IBDCedarsSinai pic.twitter.com/dnbHkhjmmH— Phillip Gu (@DrPhil_Gu) January 13, 2023

Learn more about how to prevent a C. diff infection from coming back.

Experts review treatment options for first, second and recurring episodes of Clostridioides difficile infection.

Excellent talk by @DrJessicaA on #CDiff at @CedarsSinai IM grand rounds. @AmCollegeGastro guidelines recommend AGAINST probiotics after treating for C. Diff--can actually delay reconstitution of the #microbiome! @IBDCedarsSinai pic.twitter.com/dnbHkhjmmH— Phillip Gu (@DrPhil_Gu) January 13, 2023

Enjoyed an informative #grandrounds on the diagnosis and management of #cdiff by @DrJessicaA this morning! Learned new strategies for preventing recurrent C.Diff including: 👉🏻FMT 👉🏻Bezlotoxumab👉🏻Rebyota 👉🏻More coming soon— Sarah Rotondo-Trivette, MD (@sarah_rotondoMD) January 13, 2023